Prognostic value of plasma vascular endothelial growth factor in patients with colorectal cancer

Anticancer Research

Volumn 22, Issue 4, 2002, Pages 2437-2442

  Nakayama, Yoshifumi ^a   Sako, Tatsuhiko ^a   Shibao, Kazunori ^a   Okazaki, Keisuke ^a   Rempo, Nie ^a   Onitsuka, Koji ^a   Minagawa, Noritaka ^a   Akahane, Kazuhisa ^a   Nagashima, Nobuo ^a   Nagata, Naoki ^a   Itoh, Hideaki ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

Colorectal cancer; Plasma; VEGF

Indexed keywords

VASCULOTROPIN;

ADULT; AGED; ANGIOGENESIS; CANCER GROWTH; CLINICAL ARTICLE; COLORECTAL CANCER; COLORECTAL SURGERY; CONFERENCE PAPER; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; MALE; METASTASIS POTENTIAL; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; TUMOR VASCULARIZATION;

ADULT; AGED; COLONIC NEOPLASMS; ENDOTHELIAL GROWTH FACTORS; FEMALE; HUMANS; LYMPHOKINES; MALE; MIDDLE AGED; NEOPLASM STAGING; POSTOPERATIVE PERIOD; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECTAL NEOPLASMS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0036332295     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (50)

1. What is the evidence that tumors are angiogenesis dependent?
2. The biology of vascular endothelial growth factor
3. The fibroblast growth factor family
4. Tranforming growth factor-α: A more potent angiogenic mediator than epidermal growth factor
5. Identification of angiogenic activity and the cloning and expression of platelet-derived endothelial cell growth factor
6. Interleukin-8 as a macrophage-derived mediator of angiogenesis supresses tumor groeth in vivo
7. Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo
8. The IP-10 chemokine binds to a specific cell surface heparan sulfate site shared with platelet factor 4 and inhibits endothelial cell proliferation
9. Enhanced invasive activity and decreased expression of tissue inhibitors of metalloproteinases by hepatocyte growth factor in human renal cancer cells
10. Tumor invasion and metastasis: An imbalance of positive, negative regulation
11. Effect of inhibitors of plasminogen activator, serin proteinases, and collagenase IV on the invasion of basement membranes by metastatic cells
12. Alterative expression of the collagenase and adhesion molecules in the highly metastatic clones of human colon cancer cell lines
13. a as a new prognostic factor for patients with advanced colorectal carcinoma
14. Colorectal cancer prognosis and expression of exon-v6-containing CD44 proteins
15. Pituitary follicular cells secrete a novel heparin-binding growth factor for vascular endothelial cells
16. Vascular permeability factor (VPF, VEGF) in tumor biology
17. Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets
18. Platelet: Transporter of vascular endothelial growth factor
19. Thrombocytes are the major source for soluble vascular endothelial growth factor in peripheral blood
20. Activated human neutrophils express vascular endothelial growth factor (VEGF)
21. Regulation of macrophage production of vascular endothelial growth factor (VEGF) by hypoxia and transforming growth factor beta-1
22. Synthesis, storage, and release of vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) by human mast cells: Implications for the biological significance of VEGF206
23. Peripheral blood T lymphocytes and lymphocytes infiltrating human cancers express vascular endothelial growth factor: A potential role for T cell in angiogenesis
24. Plasma VEGF as a marker of therapy in patients with chronic venous disease treated with oral micronised flavonoid fraction - A pilot study
25. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through altenative exon splicing
26. The vascular endothelial growth factor (VEGF) isoform: Differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF
27. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer
28. Prognostic value of vascular endothelial growth factor expression in gastric carcinoma
29. Association of vascular endothelial growth factor expression with tumor angiogenesis and with early relapse in primary breast cancer
30. Vessel counts and expression of vascular endothelial growth factor as prognostic factor in node-negative colon cancer
31. Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients
32. Serum vascular endothelial growth factor is often elevated in disseminated cancer
33. Concentrations of vascular endothelial growth factor in the sera of normal controls and cancer patients
34. Circulating vascular endothelial growth factor in patients with colorectal cancer
35. Preoperative serum vascular endothelial growth factor can predict stage in colorectal cancer
36. Clinical significance of plasma vascular endothelial growth factor in gastrointestinal cancer
37. Clinical usefulness of serum and plasma vascular endothelial growth factor in cancer patients: Which is the optimal specimen?
38. Correlation between vascular endothelial growth factor and tumor vascularity, and patient outcome in human gastric carcinoma
39. Plasma concentrations of VEGF and bFGF in patients with gastric carcinoma
40. Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients
41. Production of vascular endothelial growth factor by human tumors inhibits the function of dendric cells
42. Production of natural killer cell stimulatory factor-interleukin 12 by peripheral blood mononuclear cells
43. Antitumor and antimetastatic activity of interleukin 12 against murine tumors
44. Inhibition of cancer cell motility and invasion by IL-12
45. Inhibition of angiogenesis in vivo by interleukin 12
46. Multiple molecular and cellular changes associated with tumor stasis and regression during IL-12 therapy of a murine breast cancer model
47. IL-12 regulates VEGF and MMPs in a murine breast cancer model
48. Serum levels of interleukin-12 in patients with the gastrointestinal cancer
49. Relationship between plasma levels of vascular endothelial growth factor and serum levels of Interleukin-12 in patients with colorectal cancer
50. Vascular endothelial growth factor in human colon cancer: Biology and therapeutic implications